Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective

World Journal of Gastroenterology

Volumn 20, Issue 47, 2014, Pages 17737-17745

  Han, Jun Ling ^a   Lin, Hui Ling ^a  

^a 187th Hospital of PLA   (China)

Author keywords

Bile acid metabolism; Body weight; Insulin resistance; Intestinal microbiota; Type 2 diabetes

Indexed keywords

ANTIBIOTIC AGENT; ENDOCANNABINOID; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; PEPTIDE YY; PREBIOTIC AGENT; PROBIOTIC AGENT; ANTIINFECTIVE AGENT; BILE ACID; GASTROINTESTINAL HORMONE; INSULIN;

AKKERMANSIA MUCINIPHILA; ARTICLE; BACTERIA; BILE ACID METABOLISM; BODY WEIGHT; ENDOTOXEMIA; FECAL MICROBIOTA TRANSPLANTATION; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; TRANSPLANTATION; ANIMAL; BACTERIUM; CLASSIFICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; INTESTINE; METABOLISM; MICROBIOLOGY; MICROFLORA; PATHOPHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BILE ACIDS AND SALTS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL HORMONES; HOST-PATHOGEN INTERACTIONS; HUMANS; INSULIN; INSULIN RESISTANCE; INTESTINES; MICROBIOTA; NON-ALCOHOLIC FATTY LIVER DISEASE; PREBIOTICS; PROBIOTICS;

EID: 84919725262     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i47.17737     Document Type: Article

References (83)

1. International Diabetes Federation. IDF Diabetes Atlas, Sixth Edition. 2013. Available from: URL: http://www.idf.org/sites/default/files/EN-6E-Atlas-Full-0.pdf
2. Prevention of diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 844: 1-100 [PMID: 7941615]
3. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996; 4: 430-435 [PMID: 8950812]
4. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102: 11070-11075 [PMID: 16033867]
5. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023 [PMID: 17183309]
6. Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5: e9085 [PMID: 20140211 DOI: 10.1371/journal. pone.0009085]
7. Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 2013; 8: e71108 [PMID: 24013136 DOI: 10.1371/journal.pone.0071108]
8. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60 [PMID: 23023125 DOI: 10.1038/nature11450]
9. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498: 99-103 [PMID: 23719380 DOI: 10.1038/nature12198]
10. Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, Komiya K, Kawaguchi M, Shimizu T, Ogihara T, Tamura Y, Sakurai Y, Yamamoto R, Mita T, Fujitani Y, Fukuda H, Nomoto K, Takahashi T, Asahara T, Hirose T, Nagata S, Yamashiro Y, Watada H. Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes. Diabetes Care 2014; 37: 2343-2350 [PMID: 24824547 DOI: 10.2337/dc13-2817]
11. Salyers AA, Gherardini F, O'Brien M. Utilization of xylan by two species of human colonic Bacteroides. Appl Environ Microbiol 1981; 41: 1065-1068 [PMID: 7235704]
12. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-15723 [PMID: 15505215]
13. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444 : 1027-1031 [PMID: 17183312]
14. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-191 [PMID: 19126757 DOI: 10.1152/physrev.00010.2008]
15. Prabha V, Ohri M. Review: Bacterial transformations of bile acids. World J Microbiol Biotechnol 2006; 22 : 191-196 [DOI: 10.1007/s11274-005-9019-y]
16. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešiè M, Bäckhed F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17: 225-235 [PMID: 23395169 DOI: 10.1016/j.cmet.2013.01.003]
17. Kurdi P, Kawanishi K, Mizutani K, Yokota A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J Bacteriol 2006; 188: 1979-1986 [PMID: 16484210]
18. Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011; 141: 1773-1781 [PMID: 21839040 DOI: 10.1053/j.gastro.2011.07.046]
19. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res 2009; 50: 1509-1520 [PMID: 19346331 DOI: 10.1194/jlr.R900007-JLR200]
20. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, Fukamizu A. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004; 279: 23158-23165 [PMID: 15047713]
21. Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, Duez H, Velagapudi VR, Dumont J, Bouchaert E, van Dijk TH, Lucas A, Dorchies E, Daoudi M, Lestavel S, Gonzalez FJ, Oresic M, Cariou B, Kuipers F, Caron S, Staels B. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011; 60: 1861-1871 [PMID: 21593203 DOI: 10.2337/db11-0030]
22. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, Wilson-Pérez HE, Sandoval DA, Kohli R, Bäckhed F, Seeley RJ. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014; 509: 183-188 [PMID: 24670636 DOI: 10.1038/nature13135]
23. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-177 [PMID: 19723493 DOI: 10.1016/j.cmet.2009.08.001]
24. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-489 [PMID: 16400329]
25. Wewalka M, Patti ME, Barbato C, Houten SM, Goldfine AB. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab 2014; 99: 1442-1451 [PMID: 24432996 DOI: 10.1210/jc.2013-3367]
26. Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci USA 2008; 105: 13580-13585 [PMID: 18757757 DOI: 10.1073/ pnas.0804437105]
27. Sonne DP, Hansen M, Knop FK. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol 2014; 171: R47-R65 [PMID: 24760535 DOI: 10.1530/ EJE-14-0154]
28. Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. Curr Diab Rep 2014; 14: 482 [PMID: 24623198 DOI: 10.1007/s11892-014-0482-4]
29. Hotamisligil GS . Inflammation and metabolic disorders. Nature 2006; 444: 860-867 [PMID: 17167474]
30. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014; 105: 141-150 [PMID: 24798950 DOI: 10.1016/j.diabres.2014.04.006]
31. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15: 1546-1558 [PMID: 19442172]
32. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772 [PMID: 17456850]
33. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005; 11: 225-229 [PMID: 16176659]
34. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433 [PMID: 1698311]
35. Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukoc Biol 1996; 60: 8-26 [PMID: 8699127]
36. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801 [PMID: 16823477]
37. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481 [PMID: 18305141 DOI: 10.2337/db07-1403]
38. Horton F, Wright J, Smith L, Hinton PJ, Robertson MD. Increased intestinal permeability to oral chromium (51 Cr) -EDTA in human Type 2 diabetes. Diabet Med 2014; 31: 559-563 [PMID: 24236770 DOI: 10.1111/dme.12360]
39. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-1103 [PMID: 19240062 DOI: 10.1136/gut.2008.165886]
40. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, François P, de Vos WM, Delzenne NM, Schrenzel J, Cani PD. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011; 60: 2775-2786 [PMID: 21933985 DOI: 10.2337/db11-0227]
41. Scherer T, Buettner C. The dysregulation of the endocannabinoid system in diabesity-a tricky problem. J Mol Med (Berl) 2009; 87: 663-668 [PMID: 19290485 DOI: 10.1007/s00109-009-0459-y]
42. Cani PD, Geurts L, Matamoros S, Plovier H, Duparc T. Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond. Diabetes Metab 2014; 40: 246-257 [PMID: 24631413 DOI: 10.1016/j.diabet.2014.02.004]
43. Muccioli GG, Naslain D, Bäckhed F, Reigstad CS, Lambert DM, Delzenne NM, Cani PD. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010; 6: 392 [PMID: 20664638 DOI: 10.1038/msb.2010.46]
44. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 279-288 [PMID: 22572877 DOI: 10.4161/gmic.19625]
45. Bermudez-Silva FJ, Sanchez-Vera I, Suárez J, Serrano A, Fuentes E, Juan-Pico P, Nadal A, Rodríguez de Fonseca F. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007; 565: 207-211 [PMID: 17499236]
46. Aguilera M, Vergara P, Martínez V. Stress and antibiotics alter luminal and wall-adhered microbiota and enhance the local expression of visceral sensory-related systems in mice. Neurogastroenterol Motil 2013; 25: e515-e529 [PMID: 23711047 DOI: 10.1111/nmo.12154]
47. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-37 [PMID: 17159985]
48. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 2004; 54: 1469-1476 [PMID: 15388697]
49. Santacruz A, Collado MC, García-Valdés L, Segura MT, Mar-tín-Lagos JA, Anjos T, Martí-Romero M, Lopez RM, Florido J, Campoy C, Sanz Y. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr 2010; 104: 83-92 [PMID: 20205964 DOI: 10.1017/S0007114510000176]
50. Karlsson CL, Onnerfält J, Xu J, Molin G, Ahrné S, Thorngren-Jerneck K. The microbiota of the gut in preschool children with normal and excessive body weight. Obesity (Silver Spring) 2012; 20: 2257-2261 [PMID: 22546742 DOI: 10.1038/oby.2012.110]
51. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013; 110: 9066-9071 [PMID: 23671105 DOI: 10.1073/pnas.1219451110]
52. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol 2014; 20: 9072-9089 [PMID: 25083080 DOI: 10.3748/wjg.v20.i27.9072]
53. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102]
54. Duvnjak M, Lerotiæ I, Barsiæ N, Tomasiæ V, Viroviæ Jukiæ L, Velagiæ V. Pathogenesis and management issues for nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13: 4539-4550 [PMID: 17729403]
55. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 7381-7391 [PMID: 24966608 DOI: 10.3748/wjg.v20.i23.7381]
56. Gangarapu V, Yildiz K, Ince AT, Baysal B. Role of gut microbiota: obesity and NAFLD. Turk J Gastroenterol 2014; 25: 133-140 [PMID: 25003671 DOI: 10.5152/tjg.2014.7886]
57. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013; 19: 338-348 [PMID: 23452163 DOI: 10.1111/1469-0691.12140]
58. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflamma-some-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185 [PMID: 22297845 DOI: 10.1038/nature10809]
59. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19 : 6911-6918 [PMID: 24187469 DOI: 10.3748/wjg.v19.i40.6911]
60. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39: 1276-1285 [PMID: 24738701 DOI: 10.1111/apt.12758]
61. Gareth EL, Patricia LB. Glucagon-Like Peptide 1 Secretion by the L-Cell: The View From Within. Diabetes 2006; 55: S70-S77 [DOI: 10.2337/db06-S0201939-327X]
62. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 2013; 288: 25088-25097 [PMID: 23836895 DOI: 10.1074/jbc.M113.452516]
63. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM. Short-chain fatty acids stimulate glucagon-like pep-tide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012; 61: 364-371 [PMID: 22190648 DOI: 10.2337/db11-1019]
64. Cani PD, Neyrinck AM, Maton N, Delzenne NM. Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1. Obes Res 2005; 13 : 1000-1007 [PMID: 15976142]
65. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glu-cagon-like peptide 1 receptor. Diabetes 2006; 55: 1484-1490 [PMID: 16644709]
66. Delzenne NM, Cani PD, Neyrinck AM. Modulation of gluca-gon-like peptide 1 and energy metabolism by inulin and oligofructose: experimental data. J Nutr 2007; 137: 2547S-2551S [PMID: 17951500]
67. Dubé PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007; 293: E460-E465 [PMID: 17652153]
68. Shi X, Zhou F, Li X, Chang B, Li D, Wang Y, Tong Q, Xu Y, Fukuda M, Zhao JJ, Li D, Burrin DG, Chan L, Guan X. Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab 2013; 18: 86-98 [PMID: 23823479 DOI: 10.1016/j.cmet.2013.06.014]
69. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci 2003; 994: 162-168 [PMID: 12851312]
70. Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides 2012; 46: 261-274 [PMID: 22979996 DOI: 10.1016/j.npep.2012.08.005]
71. Delzenne NM, Cani PD, Daubioul C, Neyrinck AM. Impact of inulin and oligofructose on gastrointestinal peptides. Br J Nutr 2005; 93 Suppl 1: S157-S161 [PMID: 15877889]
72. Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, Danna SC, Tripathy S, Hegsted M, Keenan MJ. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 2008; 295: E1160-E1166 [PMID: 18796545 DOI: 10.1152/ajpendo.90637.2008]
73. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007; 23: 62-68 [PMID: 17084593]
74. Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 2012; 11: 29 [PMID: 22356933 DOI: 10.1186/1476-511X-11-29]
75. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012; 28: 539-543 [PMID: 22129852 DOI: 10.1016/j.nut.2011.08.013]
76. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Macé K, Chou CJ. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22: 2416-2426 [PMID: 18326786 DOI: 10.1096/fj.07-102723]
77. Chou CJ, Membrez M, Blancher F. Gut decontamination with norfloxacin and ampicillin enhances insulin sensitivity in mice. Nestle Nutr Workshop Ser Pediatr Program 2008; 62: 127-137; discussion 137-140 [PMID: 18626197 DOI: 10.1159/000146256]
78. Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit 2011; 17: RA164-RA167 [PMID: 21709646]
79. Thuny F, Richet H, Casalta JP, Angelakis E, Habib G, Raoult D. Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLoS One 2010; 5 : e9074 [PMID: 20161775 DOI: 10.1371/journal.pone.0009074]
80. Hernández E, Bargiela R, Diez MS, Friedrichs A, Pérez-Cobas AE, Gosalbes MJ, Knecht H, Martínez-Martínez M, Seifert J, von Bergen M, Artacho A, Ruiz A, Campoy C, Latorre A, Ott SJ, Moya A, Suárez A, Martins dos Santos VA, Ferrer M. Functional consequences of microbial shifts in the human gastrointestinal tract linked to antibiotic treatment and obesity. Gut Microbes 2013; 4: 306-315 [PMID: 23782552 DOI: 10.4161/gmic.25321]
81. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415 [PMID: 23323867 DOI: 10.1056/NEJMoa1205037]
82. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916.e7 [PMID: 22728514 DOI: 10.1053/j.gastro.2012.06.031]
83. Amyot J, Semache M, Ferdaoussi M, Fontés G, Poitout V. Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via Toll-Like Receptor-4 and NF-κB signalling. PLoS One 2012; 7: e36200 [PMID: 22558381 DOI: 10.1371/journal.pone.0036200]